Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts)

Authors :: Angela Gernone
Caterina Aversa
Massimo Aglietta
Sofia Torino
Imperia Nuzzolese
Fiorella Ruatta
Cinzia Ortega
Veronica Prati
Danilo Galizia
Alessandro Bonzano
Laura Marandino
Source :: Journal of Clinical Oncology. 34:e16534-e16534
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: e16534Background: AA is a potent inhibitor of CYP17; common adverse events include fluid retention and hypertension. In COU-AA-301 study a 13.3% of cardiovascular (CV) toxicity was reported. The ai...

Subjects :: 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Cardiovascular safety
business.industry
Abiraterone acetate
Prospective evaluation
03 medical and health sciences
chemistry.chemical_compound
030104 developmental biology
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
Toxicity
medicine
business
Adverse effect

Tools